Masked antibodies may open intracellular treatment route for Parkinson's disease

Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, however, antibodies have a significant limitation: They struggle to penetrate cells and are therefore largely limited to targeting molecules located on the cell surface or outside the cell.

≈